Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LEEEF | EFFECT | neutral | 3/10 | Leef Brands Inc. received SEC effectiveness on July 24, 2026 for its S-1 registration statement (File No. 333-297329), e | Jul 27, 2026 |
| RADX | 424B5 | bearish | 6/10 | Radiopharm Theranostics is raising approximately $4.05M in gross proceeds through a registered direct offering of 1,281, | Jul 27, 2026 |
| CYCN | EFFECT | mixed | 7/10 | Cyclerion Therapeutics' S-4 registration statement (File No. 333-295175) was declared effective by the SEC on July 24, 2 | Jul 27, 2026 |
| SCTX | 424B4 | neutral | 6/10 | Scribe Therapeutics priced its IPO at $15.00 per share, offering 8,580,000 shares for total gross proceeds of $128.7 mil | Jul 27, 2026 |
| LEGN | PRESS-RELEASE | neutral | 4/10 | Legend Biotech CEO Ying Huang stepped down effective July 24, 2026; Alan Bash, President of the CARVYKTI Business Unit, | Jul 27, 2026 |
| ARGX | PRESS-RELEASE | bullish | 7/10 | argenx is acquiring Forte Biosciences for $77/share in cash, total equity value ~$2.2B, an 86% premium to Forte's VWAP s | Jul 27, 2026 |
| AAPG | PRESS-RELEASE | neutral | 1/10 | Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, was ranked No. 3 in The Medicine Maker Power List 2026 Small Molecu | Jul 26, 2026 |
| KLRA | COURT-RULING | neutral | 1/10 | A federal magistrate judge granted a routine pro hac vice motion for an out-of-state attorney to represent Kailera Thera | Jul 25, 2026 |
| NVO | COURT-RULING | bearish | 6/10 | Novo Nordisk suffered a series of adverse rulings in the Griffin Health Services product liability case on July 24, 2026 | Jul 25, 2026 |
| ABT | COURT-RULING | bullish | 5/10 | The Seventh Circuit affirmed summary judgment for Abbott Laboratories in a bellwether product-liability case alleging fa | Jul 25, 2026 |
| ONC | CLUSTER | neutral | 2/10 | CEO John Oyler and SVP/GC Lee Chan Henry executed a cluster of open-market sales totaling ~$5.4M over two days, with Oyl | Jul 25, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt sold $6.3M in open-market shares over two days (July 22-23), primarily to cover taxes on exercised | Jul 25, 2026 |
| LITS | 8-K | neutral | 3/10 | Lite Strategy, Inc. filed an investor presentation on July 24, 2026, reiterating its strategy as the only Nasdaq-listed | Jul 24, 2026 |
| AZN | COURT-RULING | bullish | 6/10 | The Tenth Circuit reversed the district court's denial of PREP Act immunity for AstraZeneca in a breach-of-contract suit | Jul 24, 2026 |
| IMVT | CLUSTER | neutral | 2/10 | Two C-suite insiders at Immunovant (CFO and CTO) sold a combined $374K in open-market sales on July 23, 2026, at $38.69 | Jul 24, 2026 |
| NBP | 6-K | neutral | 3/10 | NovaBridge Biosciences filed a 6-K on July 24, 2026, announcing its Annual General Meeting (AGM) scheduled for September | Jul 24, 2026 |
| CORT | COURT-RULING | bullish | 4/10 | The court denied Teva's motion to compel Corcept to produce text messages from DOJ materials in this patent/antitrust li | Jul 24, 2026 |
| TEVA | COURT-RULING | neutral | 2/10 | Teva lost a discovery dispute in its antitrust/physician-payment lawsuit against Corcept Therapeutics. The court denied | Jul 24, 2026 |
| OTLK | 8-K | bullish | 8/10 | Outlook Therapeutics announced FDA approval of LYTENAVA (bevacizumab-vikg) for wet AMD, the first and only FDA-approved | Jul 24, 2026 |
| ONMD | 8-K | neutral | 2/10 | OneMedNet filed an 8-K setting September 18, 2026 as the date for its 2026 Annual Meeting, with an August 11 record date | Jul 24, 2026 |
| BGMS | S-4/A | bearish | 8/10 | BGMS filed Amendment No. 1 to its S-4 registration statement for the proposed reverse merger with Future NRG Sdn. Bhd., | Jul 24, 2026 |
| REPL | S-3/A | bearish | 6/10 | Replimune filed Amendment No. 1 to its S-3 shelf registration, enabling Baker Brothers affiliates to resell up to 25,103 | Jul 24, 2026 |
| MTNB | 8-K | bearish | 7/10 | BTIG, LLC terminated the at-the-market (ATM) sales agreement with Matinas BioPharma, effective immediately. The agreemen | Jul 24, 2026 |
| MNKD | 8-K | mixed | 6/10 | MannKind raised $50M via a private placement of 10.4M shares at $3.89/share and 2.4M pre-funded warrants at $3.88/share, | Jul 24, 2026 |
| CDXS | 424B5 | bearish | 6/10 | Codexis is offering 16,666,667 shares of common stock at $1.50 per share, raising approximately $23.1 million in net pro | Jul 24, 2026 |
| CPRX | 15-12G | bearish | 9/10 | Catalyst Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective July 24, 2 | Jul 24, 2026 |
| OTLK | PRESS-RELEASE | bullish | 8/10 | Outlook Therapeutics received FDA approval for LYTENAVA (bevacizumab-vikg) for wet AMD, the first and only FDA-approved | Jul 24, 2026 |
| JAGX | S-1/A | bearish | 8/10 | Jaguar Health filed a pre-effective amendment (S-1/A) to register up to 41,000,000 shares for resale by C/M Capital Mast | Jul 24, 2026 |
| CTTH | S-1/A | bearish | 6/10 | CTT Pharmaceutical Holdings filed Amendment No. 6 to its S-1 registration statement, registering 6,250,000 shares for re | Jul 24, 2026 |
| AIMD | 424B5 | bearish | 6/10 | Ainos, Inc. filed a 424B5 prospectus supplement to increase its at-the-market (ATM) offering capacity by up to $1.35 mil | Jul 24, 2026 |